Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria

Completed · Phase 2 · Has a placebo group

Conditions studied: Hyperuricemia, Albuminuria, Type 2 Diabetes

In brief

The purpose of this clinical research study is to evaluate signals of potential clinical benefit of the combination of Verinurad and Febuxostat in lowering concentrations of circulating uric acid and thus improving kidney or cardiovascular status of patients with hyperuricemia, albuminuria, and Type 2 diabetes (T2DM).

Key facts

Study ID
NCT03118739
Run by
AstraZeneca
People needed
60
Starts
2017-05-18
Expected to finish
2018-08-13
Last updated by the study team
2020-01-10

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.